US 11,986,444 B2
Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
Herriot Tabuteau, New York, NY (US)
Assigned to Antecip Bioventures II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Oct. 17, 2023, as Appl. No. 18/488,366.
Application 18/488,366 is a continuation of application No. 18/169,571, filed on Feb. 15, 2023.
Claims priority of provisional application 63/357,471, filed on Jun. 30, 2022.
Claims priority of provisional application 63/370,577, filed on Aug. 5, 2022.
Claims priority of provisional application 63/370,769, filed on Aug. 8, 2022.
Prior Publication US 2024/0050383 A1, Feb. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/137 (2006.01); A61K 9/20 (2006.01); A61K 31/485 (2006.01)
CPC A61K 31/137 (2013.01) [A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2086 (2013.01); A61K 31/485 (2013.01)] 28 Claims
 
1. A method of treating major depressive disorder in a CYP2D6 poor metabolizer comprising, selecting a human patient known to be a poor CYP2D6 metabolizer who is experiencing major depressive disorder, and administering, once daily in the morning for at least two weeks to the human patient, a dosage form containing 1 mg to 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base or another salt form of bupropion and 1 mg to 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base or another salt form of dextromethorphan, wherein the dextromethorphan AUC0-12 of the human patient is increased 208% to 557% compared to extensive or ultra-extensive CYP2D6 metabolizers.